secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-09-30T23:59:59+00:00
Accession:  0001999371-25-014216
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix sets Tonmya WAC at $1,860/month; appoints Ganesh Kamath as Head of Market Access
--------------------------------------------------------------------------------

- Tonmya (cyclobenzaprine HCl sublingual tablets) approved Aug 15, 2025 for fibromyalgia; launch expected Q4 2025.
- Wholesale acquisition cost (WAC) set at $1,860/month for 60-count supply; geriatric/mild hepatic: $930/month for 30-count.
- Ganesh Kamath appointed Head of Market Access effective Sept 29, 2025; brings 25+ years experience from Bayer, Hutchmed, CuriaGlobal.
- Kamath will lead pricing, contracting, and payer engagement for Tonmya launch and pipeline.
- First new fibromyalgia prescription therapy in over 15 years; Tonix also markets two acute migraine treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/0001999371-25-014216-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125014216/tnxp-8k_093025.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-014216

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer